Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Technology
Ragothaman Srinivasan

FORGOTTEN HISTORY: Moderna commences late stage study of flu vaccine candidate - The Untold Story

Moderna, Inc. (NASDAQ:MRNA) today announced Initiation of Patient dosing in the phase 3 clinical study of its seasonal influenza vaccine candidate mRNA-1010 for patients with influenza.

mRNA-1010 is a vaccine candidate that encodes for hemagglutinin (HA) glycoproteins of the four influenza strains recommended by the World Health Organization (WHO) for the prevention of influenza

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.